Back to top
more

CRISPR Therapeutics (CRSP)

(Delayed Data from NSDQ)

$53.91 USD

53.91
1,352,778

+0.18 (0.34%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $53.50 -0.41 (-0.76%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio

by Zacks Equity Research

Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.

Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag

by Zacks Equity Research

Madrigal Pharmaceuticals (MDGL) gains on receiving Breakthrough Therapy designation from the FDA for resmetirom.

Gamida Cell (GMDA) Surges on FDA Approval for Omisirge

by Zacks Equity Research

Gamida Cell's (GMDA) shares surge as it receives FDA approval for Omisirge, an allogeneic cell therapy for blood cancer patients.

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

by Zacks Equity Research

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed at $50.31 in the latest trading session, marking a -0.49% move from the prior day.

Regulus (RGLS) Surges on Enrollment Completion for RGLS8429

by Zacks Equity Research

Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.

Is BioRad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

by Zacks Equity Research

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-onset type 1 diabetes.

Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data

by Zacks Equity Research

Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.

Humacyte (HUMA) Completes Enrollment in HAV Technology Study

by Zacks Equity Research

Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in hemodialysis patients.

Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback

by Zacks Equity Research

Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.

Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 105.26%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 105.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Panbela (PBLA) Regains Flynpovi Rights to Treat FAP

by Zacks Equity Research

Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.

Apellis (APLS) Stock Up 50% in Three Months: Here's Why?

by Zacks Equity Research

Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.

Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag

by Zacks Equity Research

The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

by Zacks Equity Research

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

by Zacks Equity Research

Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

by Zacks Equity Research

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio

by Zacks Equity Research

Ligand's (LGND) proprietary platforms enable it to form partnerships with several leading drug companies, providing it with funds through milestone and royalty payments.

AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal

by Zacks Equity Research

Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

by Zacks Equity Research

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment

by Zacks Equity Research

InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.

CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel

by Zacks Equity Research

CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.

Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

by Zacks Equity Research

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.